No Data
Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn's and Colitis Organization 20th Annual Congress
LifeSci Capital Maintains Abivax S.A.(ABVX.US) With Buy Rating, Raises Target Price to $45
JMP Securities Maintains Abivax S.A.(ABVX.US) With Buy Rating, Maintains Target Price $33
Abivax Reaches 82% Enrollment in Phase 3 Ulcerative Colitis Trial
Abivax Announced A Milestone In The Phase 3 ABTECT Trial Of Obefazimod For Moderately To Severely Active Ulcerative Colitis
Abivax Announces a Change to the Composition of Its Board of Directors
